Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 6Phase 1/2 6

Status

Recruiting 3Active not recruiting 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 3CNS 2Tumor-Agnostic 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Brain Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 44Specimen Handling 41Carboplatin 31Magnetic Resonance Spectroscopy 28Cyclophosphamide 26Biopsy 26Nivolumab 22fludarabine 21Dexamethasone 19Gemcitabine 18Bevacizumab 16atezolizumab 14Pemetrexed 14Paclitaxel 14Docetaxel 13Cisplatin 13Rituximab 12Temozolomide 11Ipilimumab 11venetoclax 10Injections 10X-Rays 9Prednisone 9Oxaliplatin 9Fulvestrant 9Fluorouracil 9Vincristine 8Trastuzumab 8Radiotherapy 8Lenalidomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × pertuzumab × 30 days × Clear all
NCT07612215 2026-05-28

Elacestrant in Advanced Triple Positive Breast Cancer

NYU Langone Health

Phase 1/2 Recruiting
50 enrolled
Breast

Breast Neoplasms

NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT05593094 2026-05-26

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Hoffmann-La Roche

Phase 1/2 Active not recruiting
210 enrolled
CNS

Brain Neoplasms

NCT06686394 2026-05-22

MK-1022-009

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
81 enrolled
Breast

Breast Neoplasms

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Hoffmann-La Roche

Phase 1/2 Recruiting
316 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡